MedImmune And 3M Drug Delivery Systems Partner To Develop Novel TLR Agonist Cancer Therapies

MedImmune and 3M Drug Delivery Systems have announced a research collaboration focused on developing next generation toll-like receptor (TLR) agonists - promising agents that activate innate immune cells and enhance the visibility of cancer tumors.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news

Related Links:

Publication date: Available online 20 March 2019Source: Redox BiologyAuthor(s): Sin Yee Gun, Sharon Wei Ling Lee, Je Lin Sieow, Siew Cheng WongAbstractRecent years have seen a renaissance in the research linking inflammation and cancer with immune cells playing a central role in smouldering inflammation in the tumor microenvironment. Diverse immune cell types infiltrate the tumor microenvironment, and the dynamic tumor-immune cell interplay gives rise to a rich milieu of cytokines and growth factors. Fundamentally, this intricate cross-talk creates the conducive condition for tumor cell proliferation, survival and metastas...
Source: Redox Biology - Category: Biology Source Type: research
Contributors : Benny Kaipparettu ; Chad Creighton ; Yiqun Zhang ; Lee-Jun WongSeries Type : Expression profiling by arrayOrganism : Homo sapiensMicroarray analysis suggested that several oncogenic pathways observed in cybrids with cancer mitochondria are inhibited in cybrids with non-cancerous mitochondria. These results suggest the critical oncogenic regulation by motochondrial-nuclear cross talk and highlights rectifying motochondiral functional properties as a promising target in cancer therapy.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.9b00361
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
Publication date: Available online 19 March 2019Source: Carbohydrate PolymersAuthor(s): Tingting Luo, Jingtian Han, Feng Zhao, Xiaohong Pan, Baocheng Tian, Xiujuan Ding, Jing ZhangAbstractNovel chitosan-cystamine-retinoic acid conjugate (CS-SS-RA) was synthesized and could self-assemble into redox-sensitive micelles in aqueous environment with low critical micelle concentration value. CS-SS-RA micelles were characterized with spherical shape, desirable particle size, negative zeta potential, high paclitaxel (PTX) loading and encapsulation efficiency and redox-sensitivity. Hemolysis and cytotoxicity studies proved the safet...
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
Personalized Medicine, Ahead of Print.
Source: Future Medicine: Personalized Medicine - Category: Genetics & Stem Cells Authors: Source Type: research
In this issue of Molecular Cell, Zong et  al. (2019) reveal RNF168-driven chromatin ubiquitylation as a key back-up mechanism to sustain homologous recombination (HR) independently of BRCA1. These findings provide new clues to carcinogenesis and cancer therapy in BRCA1 heterozygous mutation carriers.
Source: Molecular Cell - Category: Cytology Authors: Tags: Preview Source Type: research
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Data On Racial Differences In Response To Novel Prostate Cancer Therapies. At The 2019 Genitourinary Can... Author: obr Added: 03/20/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Publication date: Available online 19 March 2019Source: European Journal of Integrative MedicineAuthor(s): Shiao Li Oei, Anja Thronicke, Matthias Kröz, Cornelia Herbstreit, Friedemann SchadAbstractIntroductionViscum album L. extracts (VA) are frequently used in integrative oncology to enhance health-related quality of life. As a central aspect of well-being is associated with feeling warm or cold the internal coherence scale (ICS) questionnaire including the thermo coherence measurement was utilized.MethodsA prospective observational longitudinal cohort study was conducted, using data from the Network Oncology clinica...
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Far too often, cancer patients and their doctors aren ’t aware of all the side effects that accompany new cancer therapies. Some of these new medications might cause fatigue, muscle aches, general pain and discomfort. A lack of information can lead to patients being unprepared to manage their symptoms or even cause some to delay or stop treatment all together. Historically, many clinical trials did not have a method to analyze or widely report the patient’s experience while undergoing a therapy.  Researchers at UCLA and across the country are trying to change that. To help people in making better-informed ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Publication date: 18 March 2019Source: Cancer Cell, Volume 35, Issue 3Author(s): Niamh McDermott, Erika S. Buechelmaier, Simon N. PowellTumors resistant to PARP inhibitors frequently show signs of replication stress, with hyper-activated PARP. In this issue of Cancer Cell, Pillay et al. demonstrate that inhibiting PAR-chain turnover results in cell-cycle arrest, which is cytotoxic when combined with cell-cycle checkpoint inhibition and constitutes a novel cancer therapy.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Medical Devices